Cellectis is the worldwide leader in the research, development and commercialization of rational genome engineering technologies. Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the Meganucleases and DNA recombination.
The DNA recognition and function of Meganucleases can be used to target a unique DNA break at a specific location within living cells. Meganucleases are acting in a site-directed fashion by inducing a highly efficient targeted DNA recombination. Rational genome engineering based on DNA recombination and Meganucleases represents an enabling technology that can be applicable to biotechnological R&D and industrial applications. More...